| TA196 |
Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196) |
|
-
-
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
NICE does not recommend imatinib as an adjuvant treatment for people after surgical removal of a GIST.
There is not enough evidence from clinical trials to say how well imatinib works as an adjuvant treatment, or whether it works well enough to justify its cost, so NICE did not recommend it.
Results from some clinical trials of imatinib as an adjuvant treatment after surgical removal of a GIST are due soon, and NICE will look at this evidence when it becomes available.
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life.
-
Other information
How this guidance was produced
Background information
This page was last updated: 30 June 2011
-
-
Guidance formats
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
